# Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer

> **NCT04671511** · NA · RECRUITING · sponsor: **Jewish General Hospital** · enrollment: 98 (estimated)

## Conditions studied

- Breast Cancer Female
- Early-stage Breast Cancer
- Lymph Node Metastases
- Axillary Metastases
- Sentinel Lymph Node

## Interventions

- **PROCEDURE:** Targeted Axillary Dissection
- **DIAGNOSTIC_TEST:** Ultrasound of the axilla

## Key facts

- **NCT ID:** NCT04671511
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-30
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671511, "Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04671511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*